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261JACC Vol. 55, No. 3, 2010 Correspondence
January 19, 2010:255–69rials had a highly selected population of diabetic patients, which may
ot be representative of the risk for cardiovascular events in the
eneral diabetic population.
Perhaps more importantly, the method for development of
UC is rigorous and does not permit alteration of the final scores
nd classification by the technical (rating) panel. Additionally, the
UC do not state that testing “must” be performed, only that it is
easonable given the clinical scenario and the available medical
nowledge/experience. AUC are therefore not equivalent to a
lass I clinical practice guideline.
Although the COURAGE nuclear substudy was underpowered
o detect differences in treatment approaches, those subjects who
xperienced a reduction of ischemia on single-positron emission
omputed tomography myocardial perfusion imaging had a supe-
ior outcome, although this difference was lost when further risk
djusted. Therefore, we agree with the opinion of Dr. Sethi and
olleagues that “routine RNI can be of use, if we can identify a
ubgroup of asymptomatic patients . . . who can benefit from
evascularization.” This thereby allows the indication to be con-
idered “appropriate” or reasonable in the parlance of AUC.
We agree that, in light of the newer trials, it may not be
ccurate to place patients with only the risk factor of diabetes
nto the high-risk category. However, based on available infor-
ation, we believe that the rating by the technical panel was
easonable. We await additional information on the best way for
isk assessment of patients and will certainly consider revising
he AUC as new evidence becomes available. Thank you for
our thoughtful comments.
Robert C. Hendel, MD, Chair,
Writing Group for RNI Appropriate Use Criteria
ichael J. Wolk, MD, Chair,
Appropriate Use Criteria Task Force
Director of Cardiac Imaging
niversity of Miami Miller School of Medicine
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ata Prior to Food and Drug
dminstration Approval
e read with great interest the recent paper by Hsich and Piña (1)
hat examined the many aspects in which we lack data for heart
ailure in women. We wholeheartedly agree that heart failure trials
ust include more women and must provide more sex-specific
ata, and we further believe that there must be evidence of net
enefit in women before Food and Drug Administration approval
or devices to be implanted in critically ill patients.
For example, the authors mention that the recent approval of
he Thoratec HeartMate II (Thoratec Corporation, Pleasanton,
alifornia) will allow more implantation of ventricular assist
evices in women and will provide prospective data through the
nteragency Registry for Mechanically Assisted Circulation regis-
ry. However, the device was approved based on data from only 44
omen, who constituted 23% of the overall study population. The
ood and Drug Administration’s Summary of Safety and Effec-
iveness Data for this device noted that the small number of
omen “makes it difficult to draw any conclusions regarding
ifferences in safety profile of the device between men and women”
2). Even so, it is worrisome that women had an increased rate of
ome important adverse events, including a 3-fold higher incidence
f stroke (18% vs. 6% in men) and trends toward a higher
ncidence of bleeding and infection events. These risks may be
orthwhile if the device had proven benefit, but it is concerning
hat the device’s success rate did not meet the pre-specified end
oint for success (2).
Therefore, we agree with the authors that a post-approval
egistry to collect data on outcomes in women for this device will
rovide needed information. However, requiring evidence of
enefit in women before Food and Drug Administration approval
or implanted devices would be an important step toward ensuring
hat we are providing safe care for women with heart failure.
anket S. Dhruva, MD
Rita F. Redberg, MD, MSc
Department of Medicine
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an Francisco, California 94143-0124
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eply
e appreciate the insightful remarks of Drs. Dhruva and Redberg
n our paper (1). We agree that to improve health care for women,
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January 19, 2010:255–69e need better reporting of sex-specific results, enrollment of
omen commensurate with the prevalence of disease, and evidence
f net benefit before approval of therapy. The Thoratec HeartMate
I (Thoratec Corporation, Pleasanton, California) is a perfect
xample of this dilemma. There was an under-representation of
omen in the trial and a trend toward more adverse events.
owever, the paucity of women prevented a final conclusion.
nfortunately, there was also no alternative life-saving therapy for
mall women when medical therapy failed and such patients
eeded long-term mechanical support to bridge them to transplan-
ation. Even pulsatile mechanical devices have a higher incidence
f neurologic events and bleeding in women compared with men,
hich further emphasizes the lack of alternative therapy and the
eed to better understand sex differences (2). The National
nstitutes of Health-sponsored Interagency Registry for Mechan-
cally Assisted Circulation database will enable us to follow sex
ifferences prospectively. Because the Thoratec HeartMate II is
eing used more extensively, the data will continue to accumulate,
nd sex-specific results will become available.
This dilemma is not unique to heart failure and must change to
educe the cardiovascular disease mortality rate in women. In a
tudy by Blauwet et al. (3) that included 628 cardiovascular trials,
nly 24% provided sex-specific results. The highest percentage of
eporting was in National Institutes of Health-sponsored studies
51% vs. 22%) and those published in general medicine journals
hen compared with cardiovascular journals (37% vs. 23%). Kim
t al. (4) subsequently published a study concentrating on National
eart, Lung, and Blood Institute-funded cardiovascular phase 3
nd 4 trials. The mean enrollment of women was lower than the
ercentage of women with that disease, and 6 of 19 trials did not
ven publish sex-specific results. This is a disappointment given
he federal mandate that requires women and minorities to be
ncluded in phase 3 and 4 clinical trials in sufficient numbers to
etermine the effectiveness of a medical intervention (5).
The effectiveness of any therapy for women can be assessed only
f sufficient numbers of women are included in clinical trials. We
oncur that it would be best to show benefit before approval of any
ew therapy and that following a post-approval registry is a
uboptimal alternative. To make it easier to enroll more women,
ational organizations should launch educational campaigns to the
ublic regarding the lack of evidence-based sex- and minority-
pecific therapy. Given the success of the Red Dress Campaign to
ncrease awareness that women are more likely to die of cardio-
ascular disease than of breast cancer, a similar campaign request-
ng them to volunteer rather than wait to be approached may be
eneficial.
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oninferiority of Pitavastatin in
ntravascular Ultrasound Findings
e read with interest the paper by Hiro et al. (1) comparing the
egressive effect of pitavastatin on coronary plaque volume in acute
oronary syndrome patients with that of atorvastatin using intra-
ascular ultrasound (IVUS). The authors demonstrated that the
pper limit of the 95% confidence interval of the difference in the
ean percentage of change in plaque volume between the 2 groups
mean 1.11%, 95% confidence interval: 2.27% to 4.48%) did not
xceed the pre-defined noninferiority margin of 5% and concluded
hat the noninferiority of pitavastatin compared with atorvastatin.
However, although an IVUS study comparing pravastatin with
torvastatin demonstrated a similar result (the difference in the
ean percentage of change in atheroma volume was 1.3%, 5.4% in
he pravastatin group and 4.1% in the atorvastatin group) (2), a
linical end point study (n  4,162) using the same drugs
emonstrated a significant difference in death or major cardiovas-
ular event rates (26.3% in the pravastatin group and 22.4% in the
torvastatin group) (3). Therefore, it remains uncertain whether
he noninferiority of pitavastatin in IVUS findings would translate
o clinical noninferiority (4). Even such a small difference in IVUS
ndings may lead to a significant difference in clinical event rates
n a large clinical trial.
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